EXTAVIA 250 micrograms/ml, powder and solvent for solution for injection 15 bottles of 1.2 ml
Active ingredients: Interferon beta-1b
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for solution for injection15 bottles of 1.2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EXTAVIA 250 microgrammes/mL, poudre et solvant pour solution injectable
- Pharmaceutical form
- poudre et solvant pour solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 15 flacon(s) en verre - 15 seringue(s) préremplie(s) en verre de 1,2 ml dans 2,25 ml
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 15 Jul 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64851088CIP72699435CIP133400926994358Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| INTERFÉRON BÊTA-1Bpoudre | 250 microgrammes · 1 ml de solution reconstituée | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.